NCI Community Oncology Research Program - Kansas City (NCORP-KC)
NCI Community Oncology Research Program - Kansas City (NCORP-KC)




Skin Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

 

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.



Melanoma

ECOG-ACRIN EA6134 - "A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma"

CANCER TYPE: Melanoma
RESEARCH BASE: ECOG-ACRIN
NCT NUMBER: NCT02224781
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Melanoma, unresectable, stage III or IV, BRAFV600 mutation, Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at progression VS. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at progression.  DCP-001 Eligible






SWOG S1320 - "A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma."

CANCER TYPE: Melanoma
RESEARCH BASE: SWOG
NCT NUMBER: 02196181
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Melanoma, Stg IV; intermittent vs continuous dosing of dabrafenib and trametinib






SWOG S1512 - "A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)

CANCER TYPE: Melanoma
RESEARCH BASE: SWOG
NCT NUMBER: NCT02775851
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 08/16/2018 (19:17:00)

Additional Consent Form: VIEW CONSENT FORM 2
UPDATED ON 08/16/2018 (19:17:00)

BRIEF DESCRIPTION

Desmoplastic melanoma, resectable or unresectable, no prior systemic tx, short term vs long term MK-3475 (pembrolizumab).






Merkel Cell Carcinoma

Alliance A091605 - "A RANDOMIZED PHASE II STUDY OF ANTI-PD1 ANTIBODY [MK-3475 (PEMBROLIZUMAB)] ALONE VERSUS ANTI-PD1 ANTIBODY PLUS STEREOTACTIC BODY RADIATION THERAPY IN ADVANCED MERKEL CELL CARCINOMA"

CANCER TYPE: Merkel Cell Carcinoma
RESEARCH BASE: Alliance
NCT NUMBER: NCT03304639
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 07/27/2018 (15:59:59)

BRIEF DESCRIPTION

Advanced or metastatic MCC, ≥ 2 cancerous deposits, MK-3475 (pembrolizumab) vs. MK-3475 (pembrolizumab) + SBRT









  © 2013-2018 All Rights Reserved. Privacy Policy | Terms & Conditions
NCI Community Oncology Research Program - Kansas City (NCORP-KC)
Questions? Call: +1-913-948-5588 | Contact Us
4121 W. 83rd St., Suite 259 Prairie Village, KS 66208 USA